Pyxis Oncology, Inc. cotiza a 1.85 USD y tiene una capitalización bursátil de $221M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with rel…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.37 | $-0.29 | $-0.35 |
| Estimado | $-0.35 | $-0.35 | $-0.34 | $-0.34 |
| Sorpresa | — | -5.7% | +14.7% | -2.9% |
| Métrica | PYXS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 82.8% | 57.0% | +25.7% |
| Operating Margin | -609.2% | -38.6% | -570.6% |
| Net Margin | -574.5% | -33.6% | -541.0% |
| FCF Margin | -458.3% | -13.9% | -444.4% |
| ROE | -149.1% | -40.4% | -108.7% |
| ROA | -87.0% | -32.0% | -55.0% |
| Current Ratio | 3.41 | 2.84 | +0.57 |
| Debt / Equity | — | 0.28 | — |